Hoofadop, Netherlands – Bioventus, a global leader in bone healing solutions, has launched a single injection of a product for the treatment of osteoarthritis (OA), DUROLAN in Malaysia, and chose Atrotech for the Malaysian market. Exclusive distribution partner.
This press release contains multimedia content. A complete press release can be found at https://www.businesswire.com/news/home/20190129005082/en/
OA can cause disintegration or degradation of the bodies of the cartilage and joints of the substrate and lubricating joint tissue. It is estimated that up to 20% of adults in Malaysia suffer from osteoarthritis, and the most common type of OP in the country is KP on the knee. from
1.DUROLANProducts containing Hyaluronic Acid (HA) can help control pain in the knees and hip in OA patients.
Bioventus CEO Tony Bihl said: "With usDUROLANAs HA products continue to grow and expand our territory in Asia, Atrotech and Bioventus are naturally suitable. Malaysia is the fourth largest market in Asia and the Biventtus is represented here.DUROLANProvides a proven NLA analgesic for more patients and doctors. "
Jeff Loah, director of Atrotech, said: "We are passionate about technologies that minimize risk and time, help patients and have unsurpassed quality.DUROLANIt is safe and patient injections can be done very quickly. This is the only injection product designed to provide powerful and long-lasting knee pain. "
Bioventus Commercial Director, John Nosenso, said: "Atrotech has a great deal of OA related to orthopedics in the condition of the disease, and we are very happy to give themDUROLANExclusive Distribution Rights. This market is a favorable combination of private, paid institutions and self-paid patients and we look forward to working together to expand our business in the long years to come. "
DUROLANBased on a natural, safe and proven technological process called NASHA®. The process produces a stable (HA), a natural molecule that provides lubrication and damping in normal joints. Studies have shown that it is better than Synvisc-One to reduce O.A.'s pain on the knee.from
®2*, relieving pain is superior to injection of steroidsfrom
3.DUROLANEqually safe for repeat treatments. Repeated useDUROLANThey did not increase the occurrence of adverse eventsfrom
Bioventus is a bone healing solution company that provides clinically proven, cost-effective products that help people recover faster and safer. The mission of the company is to help patients recover and enjoy active life, creating a difference. Products for the treatment of bones from Bioventus include products for osteoarthritis, surgery and non-surgical bone healing. Based on commitment to high quality standards, empirical medicine and ethical behavior, Bioventus is a trusted partner for doctors around the world. For more information, visit www.BioventusGlobal.com and Twitter. from
@BioventusglobalFocus on the company.
Bioventus, the logo Biovent and DUROLAN are registered trademarks of LLC Biovents. NASHA is a registered trademark of Nestle Skin Health. Synvisc-One and Synvisc are registered trademarks of Genzyme Corporation.
Display summary:Symptomatic treatment of mild to moderate arthritis of the knee or hip arthritis. No contraindications were observed. DUROLAN should not be used if there is infection or skin disease at the injection site. DUROLAN has not been tested in pregnant or lactating children. Risks may include transient pain, swelling and / or stiffness at the injection site. The reported indications are approved in Malaysia, and the indications and availability of the products vary from country to country. For locally approved use, please contact your local Bioventus representative. Full product information is available on the product label at www.DUROLANE.com.
References:1. The Malaysia Foundation for Arthritis Website http://afm.org.my/wp/?p=77. It was updated in 2015. Accessed on November 1, 2018.2. McGrath AF, McGrath AM, Jessop ZM et al. Comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate osteoarthritis of the knee. J arthritis2013, 2 (1): 108. doi: 10.4172 / 2167-7921.1000108. (McGrath AF, McGrath AM, Jessop ZM, etc. Comparison of intra-articular hyaluronic acid competitors for the treatment of mild to moderate knee arthritis 2013; 2 (1): 108. doi: 10.4172 / 2167-7921.1000108.) 3. Leighton R., Åkermark C, Therrien R, et al. NASHA hyaluronic acid vs methylprednisolone for osteoarthritis of the knee: prospective, multicentre, randomized, non-inferiority. Osteoarthritis & lt; / RTI & gt; cartilage2014; 22 (1): 17-25. (Leighton R, Åkermark C, Therrien R, etc. NASHA hyaluronic acid vs methylprednisolone for knee arthritis: prospective, multicentre, randomized, non-inferiority. Inflammatory "cartilage" 2014; 22 (1): 17-25.) 4. DUROLAN [藥品仿單]Durham, NC: Bioventus LLC; 2017.
The original version is available at businesswire.com: https://www.businesswire.com/news/home/20190129005082/en/
Disclaimer: The original version of this announcement is an officially licensed version. Translation is for your convenience only. Please refer to the original text. The original version is the only legally valid version.